Dalbavancin IV | Right Decisions

Right Decisions
Antimicrobial prescribing: NHS Grampian, Orkney & Shetland
Back
Protected (Alert) Policy
Dalbavancin IV

Announcements and latest updates

Polyfill.io vulnerability

28 june 2024

Our eHealth team advised us yesterday of an international vulnerability relating to polyfill.io . This domain has become compromised and is spreading malware through a widespread supply chain attack, estimated to affect over 110,000 websites including major websites such as the BBC. The Polyfill site offered widely used bits of code for older browsers that allowed the use of modern Javascript features. Such code makes the work for web developers easier and allows compatibility with a broader range of browsers.

Websites that have used the Javascript code from Polyfill have been urged to remove such code immediately. The change occurred after a suspected Chinese firm purchased the domain in early 2024.

Tactuum have identified and are now testing a fix to remove all Polyfill code from the RDS site.. They will be deploying the fix on Monday 1 July along with other planned fixes and amendments. I will notify you of the timing of the deployment as soon as possible.

In the meantime, please ensure that you have up-to-date anti-virus software installed on your machines and personal devices.

Permitted indications

Only on the advice of a Medical Microbiologist or Infection Specialist for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for:

2^nd line use or when Meticillin-Resistant Staphylococcus Aureus (MRSA) infection is suspected.

And

Where the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical condition does not require further inpatient treatment.

Not licensed for use in children.